trending Market Intelligence /marketintelligence/en/news-insights/trending/uzkbyw128qxyqtclowucfa2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Mundipharma launches opioid dependence drug in EU, triggers €3M payment to Orexo

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Mundipharma launches opioid dependence drug in EU, triggers €3M payment to Orexo

Orexo AB (publ) said that its partner Mundipharma GmbH has launched opioid dependence treatment Zubsolv in the EU, triggering a milestone payment of €3 million from Mundipharma.

Germany-based Mundipharma gained the rights to Zubsolv outside the U.S. in a June 2016 agreement with the Swedish drugmaker.

The treatment is in the form of a tablet, containing buprenorphine and naloxone, that is placed under the tongue.

Recently, Mylan NV and Dr. Reddy's Laboratories Ltd. gained the U.S. Food and Drug Administration's approval to market generic versions of Indivior PLC's Suboxone film, also a combination of buprenorphine and naloxone.